Boehringer Ingelheim expands immuno-oncology portfolio with Northern Biologics’ preclinical cancer antibody pipeline

Boehringer Ingelheim has bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP, whose programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology,

Read more

Boehringer Ingelheim nets breakthrough therapy designation for Ofev, for chronic fibrosing interstitial lung diseases

FDA has granted to Boehringer Ingelheim a breakthrough therapy designation for Ofev, for Chronic Fibrosing ILDs with a Progressive Phenotype, after the study results from the Phase III testing met its primary endpoint and was recently published in the New England Journal of Medicine.

Read more